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Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic
Kidney Disease and Following Selective Endothelin A Receptor
Antagonism
Neeraj Dhaun, MD, PhD;* Jale Yuzugulen, PhD;* Robert A. Kimmitt, BSc; Elizabeth G. Wood, BSc; Pajaree Chariyavilaskul, MD, PhD;
Iain M. MacIntyre, MD, PhD; Jane Goddard, MD, PhD; David J. Webb, MD, DSc; Roger Corder, PhD
Background-—Endothelin 1 (ET-1) contributes to chronic kidney disease (CKD) development and progression, and endothelin
receptor antagonists are being investigated as a novel therapy for CKD. The proET-1 peptides, endothelin-like domain peptide
(ELDP) and C-terminal pro-ET-1 (CT-proET-1), are both potential biomarkers of CKD and response to therapy with endothelin
antagonists.
Methods and Results-—We assessed plasma and urine ELDP and plasma CT-proET-1 in CKD patients with minimal comorbidity.
Next, in a randomized double-blind crossover study of 27 subjects with proteinuric CKD, we examined the effects of 6 weeks of
treatment with placebo, sitaxentan (endothelin A antagonist), and nifedipine on these peptides alongside the primary end points of
proteinuria, blood pressure, and arterial stiffness. Plasma ELDP and CT-proET-1 increased with CKD stage (both P<0.0001),
correlating inversely with estimated glomerular ﬁltration rate (both P<0.0001). Following intervention, placebo and nifedipine did
not affect plasma and urine ELDP or plasma CT-proET-1. Sitaxentan increased both plasma ELDP and CT-proET-1 (baseline versus
week 6SEM: ELDP, 11.80.5 versus 13.40.6 fmol/mL; CT-proET-1, 20.51.2 versus 23.31.5 fmol/mL; both P<0.0001).
Plasma ET-1 was unaffected by any treatment. Following sitaxentan, plasma ELDP and CT-proET-1 correlated negatively with
24-hour urinary sodium excretion.
Conclusions-—ELDP and CT-proET-1 increase in CKD and thus are potentially useful biomarkers of renal injury. Increases in
response to endothelin A antagonism may reﬂect EDN1 upregulation, which may partly explain ﬂuid retention with these agents.
Clinical Trial Registration-—URL: www.clinicalTrials.gov Unique identiﬁer: NCT00810732 ( J Am Heart Assoc. 2015;4:e001624
doi: 10.1161/JAHA.114.001624)
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C hronic kidney disease (CKD) is common and affects 6%to 11% of the population globally.1 It is strongly
associated with incident cardiovascular disease.2 As glomer-
ular ﬁltration rate (GFR) declines, the risk of cardiovascular
disease increases.3 Consequently, early detection of CKD is
important to reduce morbidity and mortality. Current mea-
sures of renal function (eg, using serum creatinine) are often
inadequate because substantial renal tissue damage must
occur before function is impaired to a detectable extent.4 An
unmet need exists for more sensitive biomarkers of renal
injury that will allow earlier detection of CKD and that will
potentially reﬂect efﬁcacy of therapy.
Endothelin 1 (ET-1) is a potent endogenous vasoconstric-
tor. It is implicated in both the development and progression
of CKD5 and plays an important role in renal salt and water
handling.6 Its effects are mediated via 2 receptors, the
endothelin A (ETA) and endothelin B (ETB) receptors, with the
major pathological effects mediated by the ETA receptor.
5
Several selective ETA and mixed ETA/B receptor antagonists
are now available and licensed for the treatment of pulmonary
arterial hypertension and scleroderma digital ulcers. Endo-
thelin receptor antagonists are also being investigated as a
novel therapeutic strategy in CKD.7 Although urinary ET-1
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excretion is well correlated with renal ET-1 production,8,9
plasma ET-1 is an unreliable measure of vascular ET-1
production because of the predominantly abluminal release
of ET-1,10 its rapid receptor-mediated uptake,5 and technical
limitations in measurement.11 Endothelin-like domain peptide
(ELDP; preproET-1[93–166])12 and C-terminal pro-ET-1 (CT-
proET-1; preproET-1[169–212]) are both cosynthesized with
ET-1 from the EDN1 gene (Figure 1). They are more stable in
the circulation and may be alternative markers of ET-1
synthesis.12
We previously investigated novel cardiovascular disease
risk factors in CKD patients across a wide range of renal
function13,14 and showed that plasma and urine ET-1 increase
as GFR declines.15 We showed recently that chronic selective
ETA receptor antagonism using the orally active drug sitaxen-
tan reduces proteinuria, blood pressure (BP), and arterial
stiffness—effects that are potentially renoprotective—in
patients with proteinuric CKD.16 We hypothesized that in
these same cohorts of patients, the proET-1 peptides ELDP
and CT-proET-1 would increase as GFR declined. Whether
sitaxentan treatment would alter proET-1 peptide levels was
unclear, but we hypothesized that any changes would relate to
changes in urine sodium excretion.
Methods
Both studies were performed with the approval of the local
research ethics committee and the written informed consent
of each subject. The investigations conformed to the princi-
ples outlined in the Declaration of Helsinki.
Observational Study: Patients With Varying
Degrees of CKD and Minimal Comorbidity
The rationale and study design have been reported in detail
elsewhere.13 In brief, subjects were recruited from the renal
outpatient clinic at the Royal Inﬁrmary of Edinburgh and
categorized into the 5 stages of CKD on the basis of the
Kidney Disease Outcome Quality Initiative (K/DOQI) classiﬁ-
cation.17 Age-matched controls were recruited from the
community. Creatinine clearance, as an estimate of GFR
(eGFR), was calculated according to the Cockcroft and Gault
equation.18 This equation was selected to assess renal
function in this study because it is more accurate than the
Modiﬁcation of Diet in Renal Disease (MDRD) equation if used
to assess mild renal insufﬁciency.19 It was further corrected
by body surface area. Blood and urine samples were obtained
from subjects after 12 hours of overnight fasting.
Interventional Study: Selective ETA Receptor
Antagonism in CKD
The rationale and design for this study have been reported
elsewhere.16 In brief, in a randomized, double-blind, 3-way
crossover study, 27 subjects on recommended renoprotective
treatment received 6 weeks of placebo, sitaxentan 100 mg
once daily, and nifedipine LA 30 mg once daily. 24-hour
proteinuria; urine protein:creatinine ratio; 24-hour ambulatory
BP; and pulse wave velocity, as an index of arterial stiffness,
were measured at baseline, week 3, and week 6 of each
treatment period. Plasma and urine ELDP and ET-1 and
plasma CT-proET-1 were also assessed at these same time
points.
Sample Collection and Analysis
ELDP, CT-proET-1, and ET-1 venous blood samples were
collected in EDTA tubes and were immediately centrifuged at
2500g for 20 minutes at 4°C. For urine ELDP, a 20-mL aliquot
of urine was collected into plain tubes. For urine ET-1, a
20-mL aliquot of urine was collected into plain tubes with
2.5 mL of 50% acetic acid. Samples were stored at 80°C
until analysis.
ELDP and CT-proET-1 were measured by sandwich ELISA
(Figure 1) using previously described methodologies.20 A well-
established format was followed using speciﬁc IgG that had
been afﬁnity puriﬁed from polyclonal sheep antisera raised
against the N- and C-terminal sequences of each peptide.
Assays were performed in 96-well plates coated with capture
Figure 1. Schematic outline of the amino acid structure of preproET-1 indicating the peptides generated
by post-translational processing. Positions of ELDP (preproET-1[93–166]) and CT-proET-1 (preproET-1
[169–212]) are shown. ET-1 is produced from big ET-1 by endothelin-converting enzyme. CT-proET-1
indicates C-terminal pro-endothelin-1; ELDP, endothelin-like domain peptide; ET-1, endothelin 1; preproET-1,
prepro-endothelin-1.
DOI: 10.1161/JAHA.114.001624 Journal of the American Heart Association 2
Pro-Endothelin-1 Peptides in CKD Dhaun et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
IgG (1 lg/mL) speciﬁc for ELDP (anti-preproET-1[93–109]
[ALENLLPTKATDRENRC]) or CT-proET-1 (anti-preproET-1[169–
186] [SSEEHLRQTRSETMRNSV]). Following overnight incuba-
tion (25 lL of plasma or 100 lL urine), detection of bound
peptide was achieved with biotinylated IgG for ELDP (prep-
roET-1[155–166] [CIYQQLVRGRKI]) or CT-proET-1 (preproET-1
[204–212] [YVTHNRAHW]), respectively. This was in conjunc-
tion with NeutrAvidin HRP (Pierce; Thermo Fisher Scientiﬁc)
and chemiluminescent substrate. Synthetic peptides were
used as assay standards.12 The lower limit of detection for
ELDP was 0.09 fmol/mL in urine and 0.30 fmol/mL in
plasma. The detection limit for CT-proET-1 in plasma was
0.60 fmol/mL. Urine CT-proET-1 could not be measured
reliably using either a double-recognition-site sandwich ELISA
or a single-site ELISA directed at the C-terminal sequence of
CT-proET-1.
After extraction,21 ET-1 was determined by radioimmuno-
assay.22 The mean recovery of ET-1, from extraction to assay,
was >90% for both plasma and urine. The intra- and interassay
variations were 6.3% and 7.2%, respectively. The cross-
reactivity of the antibody was 100% with ET-1, 7% for both ET-
2 and ET-3, and 10% with big ET-1.
Statistical Analysis
Data were statistically analyzed using GraphPad Prism version
5. Descriptive data are given as meanSD. Statistical analysis
was performed on untransformed data. Data were compared
using repeated-measures, 1-way ANOVA with Bonferroni
correction for multiple comparisons. For the observational
study, stepwise linear regression was used to identify factors
that predicted eGFR. Correlation coefﬁcients were calculated
using the Pearson method. Statistical signiﬁcance was taken
at the 5% level.
Results
Observational Study
Plasma and urine proET-1 peptides levels across CKD
stages
Subject characteristics are shown in Table 1. Plasma ELDP
concentration increased with CKD stage (P<0.0001 for trend),
with control subjects having plasma ELDP of 6.40.7 fmol/
mL compared with 12.42.5 fmol/mL for stage 5 CKD
subjects (Figure 2A). Although plasma ELDP did not differ
between control subjects and CKD patients in stages 1–3,
patients in stages 4 and 5 had higher plasma ELDP compared
with controls (P<0.001 for both). Plasma ELDP correlated
inversely with eGFR (r=0.51, P<0.0001) (Figure 2B). This
correlation was similar using both Cockcroft and Gault and
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equations. Mean urine ELDP was 1.070.11 fmol/mL with a
75-fold difference between the minimum and maximum
values of 0.09 and 6.65 fmol/L; however, there were no
differences in urine ELDP among CKD stages and no
correlation with eGFR (Figure 3).
Table 1. Subject Characteristics
Controls Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 P Value
n 23 27 30 29 20 7 —
Male/female, n 13/10 16/11 18/12 21/8 16/4 4/3 —
Smokers/nonsmokers, n 2/21 9/18 5/25 5/24 4/16 0/7 —
Serum creatinine,* mg/dL 0.90.2 0.90.2 1.10.2 2.00.6 4.11.2 7.12.0 <0.05
CrCl, mL/min per 1.73 m2 9719 10817 779 469 234 113 <0.05
Age, y 478 4311 499 5010 459 5112 NS
SBP, mm Hg 11316 11315 11613 11913 12112 13216 <0.05
DBP, mm Hg 7110 7110 749 7710 767 767 NS
MAP, mm Hg 8512 8511 8810 9110 918 958 <0.05
PP, mm Hg 429 428 417 4210 459 5617 <0.05
Body mass index, kg/m2 266 295 284 296 275 257 NS
Plasma glucose,† mg/dL 909 899 918 909 8712 9114 NS
Total cholesterol,‡ mg/dL 18930 18037 18632 17431 17032 18131 NS
Values are given as meanSD. P values are for ANOVA by chronic kidney disease stage. CrCl indicates creatinine clearance; DBP, diastolic blood pressure; MAP, mean arterial pressure;
NS, not signiﬁcant; PP, pulse pressure; SBP, systolic blood pressure.
*To convert to lmol/L, multiply by 88.4.
†
To convert to mmol/L, multiply by 0.0555.
‡
To convert to mmol/L, multiply by 0.0259.
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Plasma CT-proET-1 concentration also increased with
CKD stage (P<0.0001 for trend), with patients in stages 3,
4, and 5 having higher plasma CT-proET-1 than controls
(P<0.001, <0.0001, and <0.0001, respectively) (Figure 2C).
Plasma CT-proET-1 correlated negatively with eGFR (r=0.57,
P<0.0001) (Figure 2D). Again, this correlation was similar
using both Cockcroft and Gault and CKD-EPI equations.
Consistent with their cosynthesis, plasma ELDP correlated
with CT-proET-1 (r=0.63, P<0.0001) (Figure 4). Plasma
ELDP and CT-proET-1 showed no correlations with compo-
nents of BP or arterial stiffness in this cohort of CKD
subjects. Previously published data from this study
showed that plasma and urine ET-1 increased as eGFR
declined.13,15
A B
DC
Figure 2. Plasma ELDP (A) and CT-proET-1 (C) by stage of CKD and relationship between plasma ELPD (B)
and CT-proET-1 (D) and eGFR. *P<0.001, **P<0.0001 compared with non-CKD control subjects (stage 0).
For correlation between plasma ELDP and eGFR, r=0.51, P<0.0001. For correlation between plasma
CT-proET-1 and eGFR, r=0.54, P<0.0001. CKD indicates chronic kidney disease; CT-proET-1, C-terminal
pro-endothelin-1; eGFR, estimated glomerular ﬁltration rate; ELDP, endothelin-like domain peptide.
A B
Figure 3. Urine ELDP by stage of CKD (A) and relationship between urine ELPD and eGFR (B). CKD
indicates chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; ELDP, endothelin-like domain
peptide.
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We performed stepwise linear regression to identify factors
that predicted eGFR. We added plasma ELDP and CT-proET-1
to the previously reported factors associated with worsening
CKD in this patient population (plasma ET-1, pulse wave
velocity, ﬂow-mediated dilatation, asymmetric dimethylargi-
nine, mean arterial pressure, pulse pressure, and systolic
BP).13 In order of strongest correlation, plasma CT-proET-1,
pulse wave velocity, plasma ET-1, and mean arterial pressure
were predictors of eGFR. If plasma CT-proET-1 was not
included in the model, the predictors of eGFR in order of
strongest correlation were plasma ELDP, plasma ET-1, and
pulse wave velocity (Table 2).
Interventional Study
Effect of selective ETA receptor antagonism on plasma
proET-1 peptides
Baseline subject characteristics of those participating in the
interventional study are shown in Table 3. Data from this
study have been published previously and show that after
6 weeks of dosing, there were no signiﬁcant differences
between sitaxentan and nifedipine in the reductions from
baseline in BP parameters.16 Despite this, sitaxentan reduced
proteinuria to a signiﬁcantly greater extent than nifedipine.
Pulse wave velocity as a measure of arterial stiffness fell to a
similar degree with nifedipine as with sitaxentan. Placebo did
not affect proteinuria, BP, or pulse wave velocity (summary
data are shown in Table 4).
Baseline ELDP and CT-proET-1 concentrations were the
same for all 3 phases of the study (Table 4). Whereas placebo
and nifedipine treatments did not affect ELDP or CT-proET-1,
sitaxentan increased both peptides by 15% at both weeks 3
and 6 of the study phase (Figures 5A and 5B). Urine ELDP did
not change in any of the 3 phases of the study.
Plasma proET-1 peptides and urinary sodium excretion
Following 6 weeks treatment with sitaxentan, both plasma
ELDP and CT-proET-1 concentrations correlated inversely with
24-hour urine sodium excretion (r=0.46, P=0.01 and r=0.47,
P=0.01, respectively) (Figures 6A and 6B), whereas placebo
and nifedipine showed no such associations (Figure 7).
Changes in ELDP and CT-proET-1 did not correlate with
changes in components of BP, proteinuria, or arterial stiffness
in any of the 3 phases of the study.
Plasma and urine ET-1
Plasma ET-1 concentrations were similar at baseline in all 3
phases of the study and were not affected by any of the
interventions (Table 4). Baseline urine ET-1 levels were also
similar in all 3 phases of the study. Although placebo and
nifedipine had no impact on urine ET-1, sitaxentan reduced
this by 20% (Table 4).
Discussion
The increases in plasma ELDP and CT-proET-1 as GFR
declined support the concept that the endothelin system
contributes to CKD progression. In agreement with previous
studies of plasma ET-1 in CKD, both plasma ELDP and CT-
proET-1 were inversely correlated with GFR.13,15 These
increases are likely due in part to reduced renal clearance
from the circulation and/or to increases in synthesis. Serum
creatinine, currently the most widely used measure of renal
Figure 4. Correlation of plasma ELDP with CT-proET-1 (r=0.63,
P<0.0001). CT-proET-1 indicates C-terminal pro-endothelin-1;
ELDP, endothelin-like domain peptide.
Table 2. Multivariable Analysis of Predictors for Estimated
Glomerular Filtration Rate
Predictor Model 1 (n=120)
Model 2 (n=120;
CT-proET-1 Excluded)
Plasma ELDP 0.16 0.33*
Plasma CT-proET-1 0.44* —
Plasma ET-1 0.19† 0.31*
PWV 0.16† 0.24*
FMD 0.05 0.01
ADMA 0.04 0.07
SBP 0.20 0.10
PP 0.09 0.01
MAP 0.16† 0.13
r2 0.46 0.41
The table gives standardized regression coefﬁcients (b-values). ADMA indicates
asymmetric dimethylarginine; CT-proET-1, C-terminal pro-endothelin-1; ELDP, endothelin-
like domain peptide; FMD, ﬂow-mediated dilation of the brachial artery; MAP, mean
arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; r2, multiple coefﬁcient of
determination; SBP, systolic blood pressure.
*P<0.01.
†P<0.05.
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function, has a nonlinear relationship with GFR and begins to
rise only when GFR falls below 60 mL/min. In contrast, our
data show that ELDP and CT-proET-1 have a linear relation-
ship with GFR and begin to rise much earlier in the CKD
trajectory. Although this may make these peptides potentially
useful biomarkers of CKD, any utility beyond that provided by
serum creatinine needs to be investigated further in much
larger clinical studies with more diverse CKD populations.
Furthermore, studies that relate to the time course of CKD
progression and risk of clinical outcomes would be of
particular interest.
The CKD patients studied had minimal comorbidity, so
repeating these studies in other cohorts of patients will be
important. Our assessment of urine ELDP showed no clear
relationship with degree of CKD, but this merits further
investigation. ELDP is a recently identiﬁed peptide derived
from proET-1 that potentiates ET-1–induced vasoconstric-
tion12; therefore, data on its potential role as a biomarker or
its physiological actions are limited. By comparison, previous
studies suggest that CT-proET-1 may be a useful prognostic
biomarker in various groups of patients, including those with
pulmonary arterial hypertension,23 type 2 diabetes,24 and the
metabolic syndrome.25 Our data are the ﬁrst report of raised
levels in CKD patients. Currently, there are no data relating to
the actions of these proET-1 peptides in CKD, which should be
an area of future research.
In addition to the important evidence of potentially
renoprotective effects on proteinuria, BP, and arterial stiff-
ness, the current data show that selective ETA receptor
antagonism increases the proET-1 peptides ELDP and
CT-proET-1. There may be a number of explanations for this
ﬁnding. Although 6 weeks of sitaxentan treatment was not
associated with any change in serum creatinine, actual GFR
(measured by inulin clearance) fell from 578 to 488 mL/
min. Consequently, the rise in ELDP and CT-proET-1 may
relate to a fall in their clearance and/or an increase in
production as a result of the reduction in GFR; however, in this
phase of the study, the change in the proET-1 peptides from
baseline to week 6 did not correlate with the change in GFR.
This may be due to small sample size, but the lack of rise in
serum creatinine despite the 15% fall in real GFR highlights
the poor sensitivity of this test as a measure of GFR.
A more likely explanation for the increases in ELDP and
CT-proET-1 following sitaxentan is that ETA receptor antago-
nism interferes with the physiological negative feedback
effects of ET-1 on EDN1 gene expression.26 In support of this
explanation, early preclinical data suggested that mixed ETA/B
receptor antagonism increased plasma ET-1 to a greater
extent than selective ETB blockade.
27 Furthermore, plasma
ET-1 increased in a study administering high doses of the
ETA-selective antagonist atrasentan to healthy volunteers.
28 In
the current study, plasma ET-1 did not increase after
sitaxentan, but this is recognized as a poor marker of
vascular ET-1 production.5,10,11 An additional explanation for
the lack of rise in plasma ET-1 may be an increase in ETB
receptor–mediated clearance in the presence of a blocked ETA
receptor. Importantly, this study provides the ﬁrst clinical
evidence that increases in plasma ET-1 seen in previous
studies27,28 may be due to upregulation of its synthesis. It
would be interesting to see if other studies of selective ETA
Table 3. Baseline Subject Characteristics.
Parameter n=27
Demographic
Age, y 4812
Sex, male (%) 23 (85)
White (%) 27 (100)
Clinical
Body mass index, kg/m2 29.34.6
24-hour BP, mm Hg
Systolic 12512
Diastolic 787
Mean 948
Creatinine,* mg/dL 1.730.85
eGFR, mL/min per 1.73 m2 5426
Hemoglobin, g/L 13618
Serum potassium, mmol/L 4.60.4
Cholesterol,† mg/dL 17832
Urinary protein excretion
Grams per 24 hours 2.031.7
PCR, mg/mmol 156143
Arterial stiffness
PWV, m/s 8.32.4
cAIx, % 2812
Medications, n (%)
ACE inhibitor 18 (67)
ARB 11 (41)
ACE inhibitor plus ARB 5 (19)
No ACE inhibitor or ARB 3 (11)
a-Blocker 6 (22)
b-Blocker 8 (30)
Calcium channel blocker 3 (11)
Diuretic 2 (7)
Statin 18 (67)
Values are given as mean of 3 baseline pretreatment periodsSD. ACE indicates
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure;
cAIx, central augmentation index; eGFR, estimated glomerular ﬁltration rate; PCR,
protein:creatinine ratio; PWV, pulse wave velocity.
*To convert to lmol/L, multiply by 88.4.
†
To convert to mmol/L, multiply by 0.0259.
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receptor blockade29,30 also showed a similar rise in ELDP and
CT-proET-1. If such were the case, then this rise may be a
useful biomarker of selective ETA receptor blockade, similar to
the rise in plasma ET-1 reﬂecting effective ETB receptor
antagonism.31
Blocking ETA receptor–mediated negative feedback of
EDN1 expression may have important consequences. Edema
is a recognized side effect of both selective ETA and mixed
ETA/B receptor antagonists and has led to increased morbidity
in clinical trials.32,33 No good biomarkers currently exist for
this effect. If the increases in ELDP and CT-proET-1 are due to
upregulation of ET-1 synthesis, that could be implicated in the
renal regulation of sodium and water.6 In this study, the
correlations between plasma proET-1 peptides and urinary
sodium excretion (following dosing with sitaxentan) support
this explanation. The fall in sodium excretion with sitaxentan
will result in part from the observed fall in GFR (9 mL/min).
Nevertheless, following 6 weeks treatment with an ETA
receptor antagonist, higher plasma ELDP and CT-proET-1
concentrations were associated with lower 24-hour urine
sodium excretion. This association suggests that as proET-1
peptide concentration rises, there is renal conservation of
both salt and water. Although a rise in plasma ET-1 may be
considered to promote natriuresis and diuresis, our data also
show that urine ET-1 fell following treatment with sitaxentan.
Urine ET-1 is a measure of renal ET-1 production, so our
ﬁndings suggest that with concomitant ETA receptor blockade,
less intrarenal ET-1 may be available to act on the unblocked
tubular ETB receptor to promote salt and water excretion.
There was no correlation between the changes in proET-1
peptides and urine ET-1, although, again, this may be related
Table 4. Main Study Data At Baseline and Week 6 of Each Study Period
Placebo Sitaxentan Nifedipine
Baseline Week 6 Baseline Week 6 Baseline Week 6
24-hour proteinuria, g/day 2.060.38 2.000.33 2.070.34 1.460.26* 1.950.30 1.990.33
PCR, mg/mmol 15531 15327 15728 11423† 15527 15229
MAP, mm Hg 94.62.2 94.31.7 94.41.8 90.71.8§ 95.52.0 91.71.7§
SBP, mm Hg 125.42.7 124.21.9 124.32.2 120.71.9§ 125.72.4 120.71.6§
DBP, mm Hg 77.91.5 77.51.2 77.91.3 74.31.3* 78. 91.5 75.71.2*
PWV, m/s 7.70.3 8.00.4 8.00.3 7.60.3§ 7.90.3 7.60.3§
cAIx, % 202 202 202 152* 192 172
Plasma ELDP, fmol/mL 12.00.6 11.20.5 11.80.5 13.40.6‡ 11.30.6 11.60.5
Urine ELDP, fmol/mL 0.810.1 0.940.2 0.780.1 0.830.2 0.890.1 0.790.1
Plasma CT-proET-1, fmol/mL 20.20.9 20.21.1 20.51.2 23.31.5‡ 19.31.2 20.31.4
Plasma ET-1, pg/mL 3.60.5 3.70.6 3.60.5 3.70.5 3.50.5 3.50.5
Urine ET-1/creatinine, pg/mmol 76195 75893 78384 61381* 82497 73489
Values are given as predosing baselineSEM. cAIx indicates central augmentation index; CT-proET-1 indicates C-terminal pro-endothelin-1; DBP, diastolic blood pressure; ELDP,
endothelin-like domain peptide; ET-1, endothelin 1; MAP, mean arterial pressure; PCR, protein:creatinine ratio; PWV, pulse wave velocity; SBP, systolic blood pressure.
*P<0.01.
†
P=0.01.
‡
P<0.0001.
§
P<0.05 for week 6 vs baseline.
A
B
Figure 5. Percentage change from baseline in plasma ELDP (A)
and plasma CT-proET-1 (B) following 3 and 6 weeks of treatment
with placebo (open bar), sitaxentan (dark grey bar), and nifedipine
(light grey bar) (meanSEM, *P<0.0001 for sitaxentan at 3 or
6 weeks vs baseline). CT-proET-1 indicates C-terminal pro-endo-
thelin-1; ELDP, endothelin-like domain peptide.
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to the small sample size of this study. Furthermore, free water
clearance was not measured, but one may postulate that this
might show a similar trend to ELDP and CT-proET-1. Our
current data suggest that ELDP and CT-proET-1 merit further
investigation in patients experiencing edema with an endo-
thelin receptor antagonist because these biomarkers may
have utility in tailoring the optimal dose to reduce this side
effect. They may also encourage drug companies to continue
development of endothelin-converting enzyme inhibitors that
would effectively act as mixed ETA/B receptor blockers
without affecting ETB receptor–mediated ET-1 clearance or
perturbing the negative feedback regulation of EDN1 gene
expression mediated by ETA receptors.
Conclusions
Plasma concentrations of the proET-1 peptides ELDP and CT-
proET-1 increase as GFR declines in patients with CKD.
Measurement of ELDP and CT-proET-1 may have advantages
over the limitations associated with plasma ET-1. These
peptides may have utility in the early diagnosis of CKD and in
A B
Figure 6. Relationships between plasma ELDP (A) and plasma CT-proET-1 (B) and urine sodium excretion
following 6 weeks of treatment with sitaxentan. CT-proET-1 indicates C-terminal pro-endothelin-1; ELDP,
endothelin-like domain peptide.
A B
C D
Figure 7. Relationships between plasma ELDP and plasma CT-proET-1 and urine sodium excretion
following 6 weeks treatment with placebo (A and B) and nifedipine (C and D). CT-proET-1 indicates C-
terminal pro-endothelin-1; ELDP, endothelin-like domain peptide.
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assessing response to treatment. Furthermore, these pep-
tides may serve as potentially useful biomarkers of selective
ETA receptor antagonism and provide insights into ﬂuid
retention that is a recognized side effect in clinical trials of ET
receptor antagonists. These preliminary data need further
exploration in larger and longer clinical studies of endothelin
receptor antagonists in CKD.
Addendum
Sitaxentan has been voluntarily withdrawn by Pﬁzer, Ltd due
to unacceptable structure-related liver side effects. However,
the ﬁndings in this study are likely to be representative of the
effects of the class of selective endothelin A receptor
antagonists.
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